title: The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas.
abstract: Extrapulmonary poorly differentiated neuroendocrine carcinomas can originate in the gastrointestinal tract, bladder, cervix, and prostate. These high-grade malignancies are characterized by aggressive histological features (high mitotic rate, extensive necrosis, and nuclear atypia) and a poor clinical prognosis. They are infrequently associated with secretory hormonal syndromes (such as the carcinoid syndrome) and rarely express somatostatin receptors.Most poorly differentiated neuroendocrine carcinomas are locally advanced or metastatic at presentation. First-line systemic chemotherapy with a platinum agent (cisplatin or carboplatin) and etoposide is recommended for most patients with metastatic-stage disease; however, response durations are often short. Sequential or concurrent chemoradiation is recommended for patients with loco-regional disease. In patients with localized tumors undergoing surgical resection, adjuvant treatment (chemotherapy with or without radiation) is warranted in most cases.
authors.affiliation: Department of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA.
authors.forename: Jonathan R
authors.initials: JR
authors.lastname: Strosberg
authors.forename: Domenico
authors.initials: D
authors.lastname: Coppola
authors.forename: David S
authors.initials: DS
authors.lastname: Klimstra
authors.forename: Alexandria T
authors.initials: AT
authors.lastname: Phan
authors.forename: Matthew H
authors.initials: MH
authors.lastname: Kulke
authors.forename: Gregory A
authors.initials: GA
authors.lastname: Wiseman
authors.forename: Larry K
authors.initials: LK
authors.lastname: Kvols
mesh_terms: D018278:Carcinoma, Neuroendocrine / Q000175:diagnosis* / Q000628:therapy*; D006801:Humans